PI3K/HDAC-IN-3

• UNSPSC Description:

  PI3K/HDAC-IN-3 (36) is a PI3K and HDAC dual inhibitor, with IC50 values of 0.23 nM and 172 nM for PI3Kα and HDAC1, respectively. PI3K/HDAC-IN-3 (36) suppresses AKT phosphorylation and increased H3 acetylation in MV4-11 cells. PI3K/HDAC-IN-3 (36) exhibits significant and dose-dependent anticancer efficacy in a MV4-11 xenograft model[1].

• Target Antigen:

  HDAC; PI3K

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics;PI3K/Akt/mTOR

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pi3k-hdac-in-3.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=C2C(C(OCCCCCCC(NC3=C(C=CC=C3)N)=O)=CC(C4=CC(NS(C5=CC=C(F)C=C5F)(=O)=O)=C(OC)N=C4)=C2)=NC=N1

• Molecular Weight:

  676.73

• References & Citations:

  [1]Kehui Zhang, et al. Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia. Eur J Med Chem. 2023 Nov 30:264:116015.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3006905-22-9